Abbott Laboratories has finalized a deal with Tandem Diabetes Care Inc. to work together on automated insulin delivery systems.
Abbott said the companies will develop and commercialize systems that combine its continuous glucose monitoring technology with Tandem’s insulin delivery systems to provide more options for people to manage their diabetes.
The companies first announced plans to work together in late 2019. The agreement covers technical development of device integration and associated commercial support activities.
Abbott and Tandem Diabetes Care will focus their initial commercial activities in the U.S. and Canada, with additional geographies considered in the future.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.